Combination treatment with a SGLT2 inhibitor and exenatide may protect renal function and reduce all-cause mortality risk in patients with type 2 diabetes.
In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.
Ertugliflozin may be protective of renal function in patients with type 2 diabetes.
Linagliptin is safe for patients with type 2 diabetes and cardiorenal disease.
Findings based on 15-year follow-up study conducted among veterans with type 2 diabetes
Correlation not affected by adjustment for cardiovascular disease, end-stage renal disease
Correlation independent of major covariates including anthropometric factors and diabetes duration
In a study, men with a higher preoperative hemoglobin A1c level had greater risks for developing castration-resistant prostate cancer and metastasis.
FDA identified 55 cases of FG in patients on SGLT2 inhibitors from March 2013 through January 2019
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.